The demonstration of protein expression in tissue using antibody technology is one of the basic tools currently being used as part of targeted therapy development. Immunohistochemistry (IHC) is the major highly specialised technique that can be used to localise target or surrogate target proteins to translate events in disease processes and can be used to identify the effects of therapy.
A major advance in Pathology has been the development of digital slide scanners. Digital images of staining tissue may be stored and used for subsequent image analysis or the images can be uploaded onto secure cloud servers where remote access can be given to pathologists or clients.
The ability to quantify the expression of proteins and mRNA using IHC and ISH technologies in a consistent, accurate and reproducible way is critical and basic to current biomarker strategies used to identify efficacy, proof of concept, proof of mechanism, to develop companion diagnostics, to stratify patients and to aid the development of personalised healthcare.
Tissue is critical to the research undertaken by Histologix and through a close and long collaboration with Tissue Solutions Ltd Histologix is able to source normal and diseased human tissue from over 90 ethical biobanks world wide.
Histologix provides the Pharmaceutical and Biotechnology industry with specialist pathology services to assist drug development programmes ranging from Discovery, regulatory preclinical safety testing through to clinical trials and include human tissue sourcing, histology, medical and veterinary histopathology, immunohistochemistry, digital pathology and image analysis. These are technologies that have been developed with to meet current and future requirements of targeted therapy.
Through inward investment the services provided by Histologix Ltd use a range of highly sophisticated technologies and platforms aimed at standardising the various processes involved in order to achieve data generation that is consistent, accurate and reproducible and will assist our clients in the development of their drug programmes.
Histologix is a privately owned contract research organisation that provides specialist pathology services for the Pharmaceutical and Biotechnology industry. Set up in 2005 by industry specialists, Histologix is a GLP/GCP accredited, HTA-licenced company with an extensive and impressive track record of successfully delivering a range of IHC/ISH assays to large and small Pharma/Biotechnology companies and is a preferred supplier of these services to a number of companies.
Find out which conference Histologix is exhibiting at, updated news issues and current vacancies.